The Resource Drug class review : final report, update 4, Beta adrenergic blockers, Mark Helfand ... [et al.], (electronic book)

Drug class review : final report, update 4, Beta adrenergic blockers, Mark Helfand ... [et al.], (electronic book)

Label
Drug class review : final report, update 4, Beta adrenergic blockers
Title
Drug class review
Title remainder
final report, update 4
Title part
Beta adrenergic blockers
Statement of responsibility
Mark Helfand ... [et al.]
Title variation
Beta adrenergic blockers
Contributor
Subject
Language
  • eng
  • eng
Summary
Beta blockers inhibit the chronotropic, inotropic, and vasoconstrictor responses to the catecholamines, epinephrine, and norepinephrine. Beta blockers differ in their duration of effect (3 hours to 22 hours), the types of beta receptors they block (ø1-selective or ø1/ø2-nonselective), whether they are simultaneously capable of exerting low level heart rate increases (intrinsic sympathomimetic activity [ISA]), and in whether they provide additional blood vessel dilation effects by also blocking alpha-1 receptors. All beta blockers are approved for the treatment of hypertension. Other US Food and Drug Administration-approved uses are specific to each beta blocker and include stable and unstable angina, atrial arrhythmias, bleeding esophageal varices, coronary artery disease, asymptomatic and symptomatic heart failure, migraine, and secondary prevention of post-myocardial infarction. The objective of this review was to evaluate the comparative effectiveness and harms of beta blockers in adult patients with hypertension, angina, coronary artery bypass graft, recent myocardial infarction, heart failure, atrial arrhythmia, migraine or bleeding esophageal varices
Member of
Cataloging source
DNLM
Index
no index present
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
http://library.link/vocab/relatedWorkOrContributorName
  • Helfand, Mark
  • Drug Effectiveness Review Project.
  • Oregon Health & Science University.
  • Oregon Health & Science University
Series statement
Drug class reviews
http://library.link/vocab/subjectName
  • Adrenergic beta-Antagonists
  • Adrenergic beta-Antagonists
  • Cardiovascular Diseases
  • Treatment Outcome
  • Drug Toxicity
  • Clinical Trials as Topic
Label
Drug class review : final report, update 4, Beta adrenergic blockers, Mark Helfand ... [et al.], (electronic book)
Instantiates
Publication
Bibliography note
Includes bibliographical references
Control code
1559517
Dimensions
unknown
Extent
1 online resource.
Form of item
online
Specific material designation
remote
Label
Drug class review : final report, update 4, Beta adrenergic blockers, Mark Helfand ... [et al.], (electronic book)
Publication
Bibliography note
Includes bibliographical references
Control code
1559517
Dimensions
unknown
Extent
1 online resource.
Form of item
online
Specific material designation
remote

Library Locations

Processing Feedback ...